RNAi firms Silence Therapeutics and Intradigm combine
This article was originally published in Scrip
Executive Summary
Silence Therapeutics of the UK and privately-held US firm Intradigm are to merge in a stock-based deal that will create an enlarged RNAi-focused company with enhanced drug delivery options.